Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixekizumab (Primary) ; Adalimumab
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRIT-P1
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 15 Nov 2023 Results of post-hoc analysis, assessing the efficacy of placebo (PBO), ixekizumab (IXE) or adalimumab (ADA) on patients with erosions visible on hand radiographs at BL, presented at the ACR Convergence 2023
  • 01 Oct 2022 Results of post hoc analysis from SPIRIT-P1, SPIRIT-P2 assessing efficacy, safety, and immunogenicity published in the Clinical Rheumatology
  • 07 Apr 2022 Results assessing the updated safety profile of ixekizumab up to 3 years in patients with PsA from 4 trials (NCT01695239, NCT02349295, NCT02584855, NCT03151551) published in the Annals of the Rheumatic Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top